FAQ on GeoVax's $6 Million Public Offering and Its Implications

What is GeoVax Labs, Inc. announcing?

GeoVax Labs, Inc. is announcing a public offering to raise approximately $6 million by selling shares and warrants to institutional and individual investors.

How much does GeoVax expect to raise from this offering?

GeoVax expects to raise approximately $6 million in gross proceeds before deducting fees and expenses.

What will the proceeds from the offering be used for?

The net proceeds from the offering will be used for working capital and general corporate purposes.

When is the closing of the offering expected?

The closing of the offering is expected to occur on or about July 2, 2025, subject to customary closing conditions.

Who is acting as the placement agent for the offering?

Roth Capital Partners is acting as the exclusive placement agent for the offering.

What are the terms of the warrants being issued?

The warrants will have an exercise price of $0.65 per share, be exercisable immediately, and have a term of five years following issuance.

How can interested parties obtain more information about the offering?

Interested parties can obtain electronic copies of the final prospectus supplement and accompanying prospectus on the SEC’s website or by contacting Roth Capital Partners.

What is GeoVax’s focus in biotechnology?

GeoVax focuses on developing novel vaccines against infectious diseases and therapies for solid tumor cancers, including a next-generation COVID-19 vaccine and an oncolytic solid tumor gene-directed therapy.

Are there any ongoing clinical trials mentioned for GeoVax’s products?

Yes, GeoVax’s lead clinical program, GEO-CM04S1, a next-generation COVID-19 vaccine, is currently in three Phase 2 clinical trials, and Gedeptin®, an oncolytic solid tumor gene-directed therapy, has recently completed a multicenter Phase 1/2 clinical trial.